Front. Genet. Frontiers in Genetics Front. Genet. 1664-8021 Frontiers Media S.A. 1496683 10.3389/fgene.2024.1496683 Genetics Original Research De novo SCN1A missense variant in a patient with Parkinson’s disease Alluqmani et al. 10.3389/fgene.2024.1496683 Alluqmani Majed 1 Alayoubi Abdulfatah M. 2 Hashmi Jamil A. 2 3 Basit Sulman 2 3 * 1 Department of Neurology, College of Medicine, Taibah University Medina, Medina, Saudi Arabia 2 Department of Basic Medical Sciences, College of Medicine, Taibah University Medina, Medina, Saudi Arabia 3 Center for Genetics and Inherited Diseases, Taibah University Medina, Medina, Saudi Arabia

Edited by: Muhammad Sajid Hussain, University of Cologne, Germany

Reviewed by: Asmat Ullah, University of Copenhagen, Denmark

Muhammad Farooq, Government College University, Pakistan

 *Correspondence: Sulman Basit, sbasit.phd@gmail.com 06 11 2024 2024 15 1496683 15 09 2024 16 10 2024 Copyright © 2024 Alluqmani, Alayoubi, Hashmi and Basit. 2024 Alluqmani, Alayoubi, Hashmi and Basit

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Background

Variants in a gene encoding sodium voltage-gated channel alpha subunit 1 (SCN1A) are known to cause a broad clinical spectrum of epilepsy and associated features, including Dravet syndrome (MIM 607208), non-Dravet developmental and epileptic encephalopathy (MIM 619317), familial febrile seizures (MIM 604403), familial hemiplegic migraine (MIM 609634), and generalized epilepsy with febrile seizures (MIM 604403).

 Methods

In this study, we examined a patient with Parkinson’s disease (PD) without any clinical manifestations of epilepsy and associated features. Genomic nucleic acid was extracted, and a complete coding sequence of the human genome (whole-exome sequencing) was sequenced. Moreover, Sanger sequencing of variants of interest was performed to validate the exome-discovered variants.

 Results

We identified a heterozygous pathogenic missense mutation (c.1498C>T; p.Arg500Trp) in the SCN1A gene in the patient using the whole-exome sequencing approach. The onset of PD features in our patient occurred at the age of 30 years. Biochemical investigations were carried out to rule out any secondary cause of the disease, including Wilson's disease or another metabolic disorder. MRI of the brain and spinal images were unremarkable. Moreover, a dramatic response to carbidopa–levodopa treatment was also observed in the patient.

 Conclusion

Our results suggest that the pathogenic variant in SCN1A may lead to PD features without epilepsy.

 Parkinson’s disease SCN1A gene mutation exome sequencing no epilepsy section-at-acceptance Applied Genetic Epidemiology Introduction

Parkinson’s disease (PD) is a neurodegenerative disease characterized by motor and non-motor symptoms. Motor symptoms include bradykinesia, rigidity, and resting tremor, while non-motor symptoms observed in PD are cognitive impairment, constipation, fatigue, sleep disturbance, and depression (Berardelli et al., 2001; Zesiewicz et al., 2003; Aarsland et al., 2009; Baradaran et al., 2013; Williams and Litvan, 2013; Zhu et al., 2016; Loddo et al., 2017; Gironell et al., 2018; Dulski et al., 2019; Balestrino and Schapira, 2020). PD is a complex disease with clinical and genetic heterogeneity. It occurs in autosomal recessive (AR), autosomal dominant (AD), and in X-linked forms. The autosomal recessive forms of Parkinson’s disease can be divided into juvenile [type 2 (MIM 600116) and type 19b (MIM 608375)] and early-onset [type 6 (MIM 605909), type 7 (MIM 606324), type 19b (MIM 615528), type 20 (MIM 615530), and type 23 (MIM 616840)] Parkinson’s disease. Late-onset Parkinson’s disease has been observed mostly in autosomal dominant cases. Genes associated with Parkinson’s disease include PARK1, PARK3, PARK7 (DJ1), PARK10, PARK12, PARK16, ATP13A2, PINK1, DNAJC6, GBA, HTRA2, GIGYF2, EI4G1, UCHL1, SNCA, ADH1C, PRKN, TBP, CHCHD2, LRRK2, ATXN2, ATXN8OS, VPS13C, VPS35, MAPT, SYNJ1, FBXO7, PLA2G6, and GLUD2 (Hardy, 2010). More than 100 genetic loci have been associated with PD and other forms of Parkinsonism (Dulski et al., 2022). Sequencing of the human genome is becoming cost-effective, which, in turn, leads to more widespread application in research and clinical settings. In particular, whole-exome sequencing (WES) and genome-wide association studies (GWAS) have been instrumental in identifying new variants or combinations of multiple variants (oligo- and polygenic inheritance) in PD patients.

We have applied the WES approach to a patient with a classic PD phenotype. Initially, all known PD-associated genes were screened using the neurodegenerative disease panel for the potential genetic variant. No candidate variant was found in the PD-associated genes. The hypothesis-free unbiased variant prioritization approach identified a pathogenic variant in the SCN1A gene. Although variants in the SCN1A gene have been reported in various epileptic conditions, our patient was found to be free of any type of epileptic condition.

 Materials and methods Blood collection and genomic DNA extraction

Blood samples from five members of one family, including both parents (IV:1 and IV:2), one affected individual (V:2), and two unaffected siblings (V:1 and V:3) were collected in EDTA-containing vacutainers (Figure 1A). Ethical approval for the study was obtained from the research ethics committee (REC) of the College of Medicine, Taibah University Medina, Saudi Arabia. Informed written consent for genetic studies in Arabic and in English was obtained from all participants. Genomic DNA was extracted using the QIAmp DNA isolation kit (Venlo, Netherlands). DNA was quantified using a spectrophotometer.

Five-generation pedigree structure of a family with an individual (V:2) with Parkinson’s disease (A). Partial sequence chromatogram of a parent (B) and the patient (C). The heterozygous sequence is marked with an arrowhead (C).

The patient was examined by a consultant neurologist, and an MRI was performed to detect any structural brain abnormalities.

 Whole-exome sequencing of a DNA sample from the patient

Genomic DNA (250 ng) from the patient (V:2) was used to generate whole-exome amplicons using the Illumina library preparation kit. For this purpose, the Illumina DNA Prep with Exome 2.0 Plus Enrichment kit (San Diego, CA, United Stated) was used. This kit uses bead-linked transposomes and comprehensively covers all the coding exons (37.5-Mb coding content including ≥99% of RefSeq) and variants across public databases (ClinVar and ACMG pathogenic/likely pathogenic variants, COSMIC Cancer Gene Census). DNA libraries were prepared, followed by enrichment and post-enrichment amplification. The whole-exome sequencing protocol used here can be found elsewhere (Rafiullah et al., 2022; Ullah et al., 2022).

Exome libraries were enriched and sequenced on an Illumina NextSeq500 instrument (San Diego, CA, United States). Sequencing reads were collected in base calling (.bcl) files.

 Sanger sequencing of exome-discovered variants of interest

In order to confirm variants detected by exome sequencing, the Applied Biosystems™ (Foster City, CA, United States) capillary electrophoresis (CE)-based genetic analyzer platform and BigDye™ Direct Cycle Sequencing Kit (Foster City, CA, United States) and variant-specific primer sets were used to Sanger sequence-specific amplicons. Unincorporated nucleotides and primers were then removed using the BigDye XTerminator™ Purification Kit. Sequence chromatograms were generated by standard CE. The sequences obtained were read by SeqA software. Moreover, potential candidate variants were also Sanger sequenced in both parents and unaffected individuals to evaluate the segregation of variants.

 Results Clinical description

The patient was examined in an adult neurology clinic of King Fahd Hospital Medina by a consultant neurologist. He presented, at the age of 30 years, with stiffness in his left leg while performing his daily activities. He had no prior history of any medical condition or surgical treatment. The asymmetric stiffness worsened with the increasing severity of the pain. Three years later, at the age of 33, intermittent resting tremor of the left hand was observed. Progression of the tremor to the contralateral hand was also observed subsequently. Myerson’s sign (glabellar reflex) was present. Moderate signs of asymmetrical cogwheel rigidity and bradykinesia were also observed. The gait showed typical Parkinson’s disease features (small shuffling steps and reduced arm swing on the left side) and normal postural reflexes. At the age of 36 years, prominent signs of PD such as unintended movements, stiffness, and difficulties with balance and coordination, were observed (Table 1).

Motor and non-motor symptoms identified in the patient with Parkinson’s disease.

Motor symptom Non-motor symptom
Intermittent resting tremor Depression
Postural instability Sleep disorder
Hypophonic speech Constipation
Cogwheel rigidity
Bradykinesia

Neurological examination revealed normal cognition. An oculomotor examination was also unremarkable. Magnetic resonance imaging (MRI) of the brain did not reveal any structural abnormality (Figure 2).

MRI of the brain of an individual showing features of Parkinson’s disease. T2 flair axial (A), brain T2 (B), and brain Sagittal T2 (C) were unremarkable.

We followed the patient for more than 6 years in an outpatient clinic. He has been on carbidopa–levodopa medication for the last 3 years. Sinemet (25/250 mg) was prescribed for him three times a day; however, no significant improvement was observed.

 WES discovered a missense variant in the <italic>SCN1A</italic> gene

The patient's DNA sample was exome-sequenced to identify the variant(s) underlying the PD phenotype. Analysis of the reads was carried out by aligning the exome reads to the reference genome, followed by variant calling to identify disease-associated variants. The average read length was 150bps, and the average throughput depth of the target regions was 219x. It was observed that 99.8% of reads were mappable. The mean depth of the target regions was 81.6x, and the percentage coverage of the target regions (≥30x) was 92.2%. Variants were filtered using QIAGEN Clinical Insight (QCI) and Genoox Franklin (https://franklin.genoox.com/analysis-tool) tools. The variant interpretation was performed using VarSome, SIFT, PolyPhen, ClinVar, and other prediction tools. Details of the exome data analysis are available elsewhere (Raza et al., 2022; Zaka et al., 2021).

A rare homozygous variant in NRAP (NM_006175.5; c.919G>A; p.G307R), compound heterozygous variants in TTN (NM_003319.4; c.28328G>A; p.G9443E and NM_003319.4; c.68747A>G; p.Y22916C), and a heterozygous variant in SCN1A (NM_001165963.4; c.1498C>T; p.Arg500Trp) genes were filtered and considered to be potential candidate variants for the disease. Variants were classified using ACMG guidelines (Table 2). These variants were further evaluated based on their expression and function using the UCSC genome browser (https://genome.ucsc.edu/) and GeneCards (https://www.genecards.org/). Moreover, PubMed (https://pubmed.ncbi.nlm.nih.gov/) was also searched for the literature related to mutations in these genes. Furthermore, Sanger sequencing was also performed to validate the exome-discovered variants and for segregation analysis within the pedigree. RNA-Seq expression data from GTEx show no expression of TTN and NRAP in any part of the brain and tibial nerve. Therefore, both TTN and NRAP variants were not considered candidates for the PD phenotype observed in our patient. SCN1A is highly expressed in the different parts of the brain, specifically in the frontal cortex. Moreover, the variant (c.1498C>T) in SCN1A is absent in 110 ethnic control DNAs. Therefore, we considered the heterozygous variant in the SCN1A gene as a candidate variant for the PD phenotype.

Variants identified and prioritized during whole-exome sequence data analysis.

Gene/variant gnomAD frequency CADD PolyPhen PyloP Computed classification
NRAP: c.919G>A; p.G307R 0.000004337 Deleterious Probably damaging Highly conserved Uncertain significance
TTN: c.28328G>A; p.G9443E Absent Deleterious Probably damaging Highly conserved Uncertain significance
TTN: c.68747A>G; p.Y22916C Absent Deleterious Probably damaging Highly conserved Uncertain significance
SCN1A: c.1498C>T; p.Arg500Trp 0.000005577 Deleterious Probably damaging Highly conserved Likely pathogenic
Sanger sequencing confirmed the <italic>de novo</italic> nature of the <italic>SCN1A</italic> variant

Primers were designed for the missense variant in SCN1A (NM_001165963.4; c.1498C>T; p.Arg500Trp) and the variant was bi-directionally sequenced in all the available individuals, including both parents. The patient’s DNA carries the variant in the heterozygous state (Figure 1C); however, the variant is not present in either parent’s DNA (Figure 1B). Therefore, it is considered a de novo variant.

 Discussion

PD is the second most common neurodegenerative disease and is characterized by misfolding and aggregation of α-synuclein in the cytoplasm of the neurons (Lewy bodies), leading to progressive loss of dopaminergic (DA) neurons in the pars compacta of the substantia nigra (SNpc) (Balestrino and Schapira, 2020). DA neurons are the main source of dopamine in the mammalian CNS (Chinta and Andersen, 2005). Therefore, they are essential for voluntary movement, cognition, emotion, working memory, and reward pathways (Chinta and Andersen, 2005; Salgado-Pineda et al., 2005; Bromberg-Martin et al., 2010; McNamara et al., 2014). Insufficient dopamine levels not only cause disabling motor symptoms but also lead to mood changes and memory loss (Chinta and Andersen, 2005). DA neurons have spontaneous action potential firing (pacemaker properties) ability (Puopolo et al., 2007; Guzman et al., 2009). This distinct electrical activity is important for dopamine secretion. Ion channel activities, including voltage-gated sodium channels, control the pacemaker frequency (Tucker et al., 2012; Ilin et al., 2021). Therefore, we hypothesize that mutations affecting the function or expression of voltage-gated sodium channels may be responsible for neurological disorders, including PD.

PD segregates in both autosomal dominant and autosomal recessive forms. Mutations in several genes have been found as the underlying cause of PD (Klein and Westenberger, 2012). Genetic mutations underlying PD or PD risk factors can be delineated using gene mapping, candidate gene sequencing, genome-wide association studies, or whole-exome and whole-genome sequencing approaches. Gene mapping, exome, and genome sequencing approaches usually use hypothesis-free approaches to identify the genetic variant underlying the phenotype.

Here, in this study, we also used a hypothesis-free approach and sequenced the complete coding part of the human genome in a DNA sample from a patient with a classical PD phenotype. We identified a deleterious heterozygous missense variant (c.1498C>T; p.Arg500Trp) in a SCN1A gene in a patient with a typical PD phenotype. Mutations in the SCN1A gene are known to cause autosomal dominant Dravet syndrome (MIM 607208), non-Dravet developmental and epileptic encephalopathy (MIM 619317), familial febrile seizures (MIM 604403), familial hemiplegic migraine (MIM 609634), and generalized epilepsy with febrile seizures (MIM 604403). Seizures and ophthalmological abnormalities (nystagmus—visual impairment) are hallmarks of the SCN1A phenotype. For instance, the same heterozygous variant (c.1498C>T; p.Arg500Trp) in the SCN1A gene has been reported in a patient with refractory seizures and cognitive impairment (Nashabat et al., 2019). However, our patient is free of seizures and eye abnormalities. Moreover, the brain MRI of the patient did not show any structural abnormality. The same disease-causing variant underlying different clinical phenotypes may be due to variable penetrance and expressivity. Studies have shown that modifier genes, genetic background, and complex genetic and environmental interactions can cause phenotypic variation (Kammenga, 2017).

Therefore, we hypothesize that de novo variants of SCN1A are the underlying cause of autosomal dominant PD. However, there are some limitations, and further research is needed to validate and confirm our findings. For instance, WES analysis is limited to variants in the coding part and flanking regions of exons. Homozygous or compound heterozygous variants in the non-coding part and copy number variations are missed by WES analyses.

 Data availability statement

The original contributions presented in the study are publicly available. This data can be found here: https://www.ncbi.nlm.nih.gov/biosample/44076318. The accession number is SAMN44076318.

 Ethics statement

The studies involving humans were approved by the Research Ethics Committee, Taibah University, Medina, Saudi Arabia. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

 Author contributions

MA: funding acquisition, investigation, methodology, resources, validation, and writing–review and editing. AMA: funding acquisition, methodology, and writing–review and editing. JH: data curation, formal analysis, investigation, methodology, software, and writing–original draft. SB: conceptualization, investigation, software, supervision, validation, writing–original draft, and writing–review and editing.

 Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors extend their appreciation to the King Salman Center for Disability Research, Riyadh, Saudi Arabia, for funding this work through Research Group no. KSRG-2022-088. The funding body played no role in the design of the study and collection, analysis, and interpretation of the data and in writing the manuscript.

The authors are thankful to patients and their family members for their participation and contribution to this work.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Aarsland D. Marsh L. Schrag A. (2009). Neuropsychiatric symptoms in Parkinson’s disease. Mov. Disord. 24 (15), 2175–2186. 10.1002/mds.22589 Balestrino R. Schapira A. H. V. (2020). Parkinson disease. Eur. J. Neurol. 27, 27–42. 10.1111/ene.14108 Baradaran N. Tan S. N. Liu A. Ashoori A. Palmer S. J. Wang Z. J. (2013). Parkinson’s disease rigidity: relation to brain connectivity and motor performance. Front. Neurol. 4, 67. 10.3389/fneur.2013.00067 Berardelli A. Rothwell J. C. Thompson P. D. Hallett M. (2001). Pathophysiology of bradykinesia in Parkinson’s disease. Brain 124 (11), 2131–2146. 10.1093/brain/124.11.2131 Bromberg-Martin E. S. Matsumoto M. Hikosaka O. (2010). Dopamine in motivational control: rewarding, aversive, and alerting. Neuron 68 (5), 815–834. 10.1016/j.neuron.2010.11.022 Chinta S. J. Andersen J. K. (2005). Dopaminergic neurons. Int. J. Biochem. Cell Biol. 37 (5), 942–946. 10.1016/j.biocel.2004.09.009 Dulski J. Schinwelski M. Konkel A. Grabowski K. Libionka W. Wa̧ż P. (2019). The impact of subthalamic deep brain stimulation on sleep and other non-motor symptoms in Parkinson’s disease. Park. Relat. Disord. 64, 138–144. 10.1016/j.parkreldis.2019.04.001 Dulski J. Uitti R. J. Ross O. A. Wszolek Z. K. (2022). Genetic architecture of Parkinson's disease subtypes - review of the literature. Front. Aging Neurosci. 14, 1023574. PMID: 36337703; PMCID: PMC9632166. 10.3389/fnagi.2022.1023574 Gironell A. Pascual-Sedano B. Aracil I. Marín-Lahoz J. Pagonabarraga J. Kulisevsky J. (2018). Tremor types in Parkinson disease: a descriptive study using a new classification. Parkinson’s Dis. 2018, 4327597. 10.1155/2018/4327597 Guzman J. N. Sánchez-Padilla J. Chan C. S. Surmeier D. J. (2009). Robust pacemaking in substantia nigra dopaminergic neurons. J. Neurosci. 29 (35), 11011–11019. 10.1523/JNEUROSCI.2519-09.2009 Hardy J. (2010). Genetic analysis of pathways to Parkinson disease. Neuron 68 (2), 201–206. PMID: 20955928; PMCID: PMC2997424. 10.1016/j.neuron.2010.10.014 Ilin V. A. Bai Q. Watson A. M. Volgushev M. Burton E. A. (2021). Mechanism of pacemaker activity in zebrafish DC2/4 dopaminergic neurons. J. Neurosci. 41 (18), 4141–4157. 10.1523/JNEUROSCI.2124-20.2021 Kammenga J. E. (2017). The background puzzle: how identical mutations in the same gene lead to different disease symptoms. FEBS J. 284 (20), 3362–3373. 10.1111/febs.14080 Klein C. Westenberger A. (2012). Genetics of Parkinson's disease. Cold Spring Harb. Perspect. Med. 2 (1), a008888. PMID: 22315721; PMCID: PMC3253033. 10.1101/cshperspect.a008888 Loddo G. Calandra-Buonaura G. Sambati L. Giannini G. Cecere A. Cortelli P. (2017). The treatment of sleep disorders in Parkinson’s disease: from research to clinical practice. Front. Neurol. 8, 42. 10.3389/fneur.2017.00042 McNamara C. G. Tejero-Cantero Á. Trouche S. Campo-Urriza N. Dupret D. (2014). Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence. Nat. Neurosci. 17 (12), 1658–1660. 10.1038/nn.3843 Nashabat M. Al Qahtani X. S. Almakdob S. Altwaijri W. Ba-Armah D. M. Hundallah K. (2019). The landscape of early infantile epileptic encephalopathy in a consanguineous population. Seizure 69, 154–172. Epub 2019 Apr 27. PMID: 31054490. 10.1016/j.seizure.2019.04.018 Puopolo M. Raviola E. Bean B. P. (2007). Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J. Neurosci. 27 (3), 645–656. 10.1523/JNEUROSCI.4341-06.2007 Rafiullah R. Albalawi A. M. Alaradi S. R. Alluqmani M. Mushtaq M. Wali A. (2022). An expansion of phenotype: novel homozygous variant in the MED17 identified in patients with progressive microcephaly and global developmental delay. J. Neurogenet. 12, 108–114. Epub ahead of print. PMID: 36508181. 10.1080/01677063.2022.2149748 Raza R. Ullah A. Haider N. Krishin J. Shah M. Khan F. U. (2022). Exome sequencing reveals the first intragenic deletion in ABCA5 underlying autosomal recessive hypertrichosis. Clin. Exp. Dermatol 12, 1137–1143. Epub ahead of print. PMID: 35150007. 10.1111/ced.15128 Salgado-Pineda P. Delaveau P. Blin O. Nieoullon A. (2005). Dopaminergic contribution to the regulation of emotional perception. Clin. Neuropharmacol. 28 (5), 228–237. 10.1097/01.wnf.0000185824.57690.f0 Tucker K. R. Huertas M. A. Horn J. P. Canavier C. C. Levitan E. S. (2012). Pacemaker rate and depolarization block in nigral dopamine neurons: a somatic sodium channel balancing act. J. Neurosci. 32 (42), 14519–14531. 10.1523/JNEUROSCI.1251-12.2012 Ullah A. Shah A. A. Alluqmani M. Haider N. Aman H. Alfadhli F. (2022). Clinical and genetic characterization of patients segregating variants in KPTN, MINPP1, NGLY1, AP4B1, and SON underlying neurodevelopmental disorders: genetic and phenotypic expansion. Int. J. Dev. Neurosci. 82 (8), 788–804. Epub 2022 Oct 11. PMID: 36181241. 10.1002/jdn.10231 Williams D. R. Litvan I. (2013). Parkinsonian syndromes. Continuum 19 (5), 1189–1212. 10.1212/01.CON.0000436152.24038.e0 Zaka A. Shahzad S. Rao H. Z. Kanwal S. Gul A. Basit S. (2021). An intrafamilial phenotypic variability in Ellis-Van Creveld syndrome due to a novel 27 bps deletion mutation. Am. J. Med. Genet. A 185 (10), 2888–2894. Epub 2021 May 26. PMID: 34037314. 10.1002/ajmg.a.62360 Zesiewicz T. A. Baker M. J. Wahba M. Hauser R. A. (2003). Autonomic nervous system dysfunction in Parkinson’s disease. Curr. Treat. Options Neurol. 5 (2), 149–160. 10.1007/s11940-003-0005-0 Zhu M. Li M. Ye D. Jiang W. Lei T. Shu K. (2016). Sensory symptoms in Parkinson’s disease: clinical features, pathophysiology, and treatment. J. Neurosci. Res. 94 (8), 685–692. 10.1002/jnr.23729